Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals
CRNX | NASDAQ
Chart Builder DCF Calculator
$84.95
$0.00 (0.00%)
At close: Aug 31, 2026, 4:00 PM ET

Crinetics Pharmaceuticals Company Profile

Company profile explained

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Key Executives

Name Position
R. Scott Struthers Founder, President, Chief Executive Officer & Director
Garlan Adams Chief Legal Officer & Corporate Secretary
Kea Lingo Chief Information Officer
Tobin C. Schilke Chief Financial Officer
Adriana Cabre Chief Human Resources Officer
Alan S. Krasner Chief Endocrinologist
Chris Robillard Chief Business Officer
Gayathri Diwakar Head of Investor Relations
Kevin Capps Head of Intellectual Property
Natalie Badillo Head of Corporate Communications
Stephen F. Betz Co-Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Sep 11, 2026 15-12G Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
Sep 01, 2026 4 Filing
View All SEC Filings ➞
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals logo
Country United States
IPO Date Jul 18, 2018
Industry Biotechnology
Sector Healthcare
Employees 594
CEO R. Scott Struthers

Contact Details

6055 Lusk Boulevard San Diego, California 92121 United States

Stock Details

Ticker Symbol CRNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001658247
CUSIP Number 22663K107
ISIN Number US22663K1079
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.